Gilead Sciences, Inc. vs Regents of the University of Minnesota

Notice of Refund

Petitioner's Request for Refund

Trial Instituted Document

Granting Petitioners Motions for Pro Hac Vice Admission of Nevin M. Gewertz, Adam K. Mortara, J. Scott McBride, and Robert S. Schwartz 37 C.F.R. sec 42.10

Petitioner's Fourth Amended Mandatory Notices

Petitioner's Updated Power of Attorney

Petitioner's Authorized Table of Supplemental Authority

Zinzani et al. 2000

Sallah et al. 2001

De Clercq, 2005

Physicians' Desk Reference 2002 ("PDR")

McGraw-Hill Dictionary of Scientific and Technical Terms 1994 ("McGraw-Hill")

Patent Owner's Preliminary Response

Loudon 1995

Nabhan et al. 2001

Kremer 1975

IPR2017-01712 Petition

IPR2017-01753 Petition

Patent Owner's Response to Petitioner's Notice of Ranking Petitions

Petitioner's Notice

Conduct of the Proceeding 37 C.F.R. ¿¿ 42.5

ORDER Granting Patent Owner's Motion to Substitute Lead Counsel

Patent Owner's Unopposed Motion to Substitute Lead Counsel

Patent Owner's Updated Power of Attorney

Patent Owner's Second Updated Mandatory Notices

Denying Patent Owner's Motion to Dismiss

Patent Owner's Notice of Denial of Petition for Cert in Regents of the University of Minnesota v. LSI Corp.

PANEL CHANGE ORDER Conduct of the Proceedings 37 C.F.R. ¿¿ 42.5

Transcript of August 20, 2019 Conference Call

Patent Owner's Notice of Filing Transcript of August 20, 2019 Conference Call

Exhibit 3001

Decision - 37 C.F.R. 42.71(b)

Exhibit 3002

Petitioner¿¿¿s Third Amended Mandatory Notices

Petitioner's Second Amended Mandatory Notices

Decision Denying Petitioner's Request for Rehearing

Petitioner's Request for Rehearing

Preliminary Amendment, U.S. Patent Application No. 14/229,292, (Mar. 31, 2014)

Order, Regents of the University of Minnesota v. Gilead Sciences, Inc., Civil Action No. 0:16-cv-02915-SRN-HB, D.I. 139 (D. Minn. Jun. 9, 2017)

January 26, 2018 Email Chain Between Counsel for Petitioner and Counsel for Patent Owner

January 28, 2018 Email from Counsel for Petitioner to Board and Counsel for Patent Owner

Stipulation and Proposed Order to Exclude Filings From IPR Proceedings, Regents of the Univ. of Calif. v. St. Jude Medical, LLC (N.D. Cal. Feb. 2, 2018)

Order, Regents of the University of Minnesota v. AT&T Mobility LLC (D. Minn. May 19, 2017)

Gilead's Motion to Stay Pending Inter Partes Review, Regents of the University of Minnesota v. Gilead Sciences, Inc., 17-cv-6056-VC, D.I. 297 (N.D. Cal. Feb. 7, 2018)

Transcript of October 24, 2017 Conference Call

Stipulated Case Management Statement, Regents of the University of Minnesota v. Gilead Sciences, Inc., 17-cv-6056-VC, D.I. 275 (N.D. Cal. Jan. 2, 2018)

January 26, 2018 Email from Counsel for Patent Owner to Board and Counsel for Petitioner

Petitioner's Second Amended Exhibit List

Conduct of the Proceeding

Patent Owner Regents of the University of Minnesota's Reply in Support of its Motion to Dismiss

Gilead Sciences, Inc. Opposition to Regents of the University of Minnesota's Motion to Dismiss

Petitioner's First Amended Mandatory Notices

Patent Owner's Updated Mandatory Notices

Patent Assignment

Patent Owner's Motion to Dismiss

University of Minnesota Charter

University of Minnesota's Consolidated Financial Statements (2015 & 2016)

Gilead Sciences, Inc.'s Answer to Plaintiff's Complaint for Patent Infringement

Conduct of the Proceeding

Petitioner's Motion For Admission Pro Hac Vice Of Nevin M. Gewertz Under 37 C.F.R. 42.10(c)

Declaration of Nevin M. Gewertz

Petitioner's Motion For Admission Pro Hac Vice Of Adam K. Mortara Under 37 C.F.R. 42.10(c)

Declaration of Adam K. Mortara

Petitioner's Motion For Admission Pro Hac Vice Of J. Scott McBride Under 37 C.F.R. 42.10(c)

Declaration of J. Scott McBride

Petitioner's Motion For Admission Pro Hac Vice Of Robert S. Schwartz Under 37 C.F.R. 42.10(c)

Declaration of Robert S. Schwartz

Petitioner's First Amended Exhibit List

Notice of Accord Filing Date

Patent Owner's Mandatory Notices

Power of Attorney

U.S. Patent No. 8,815,830

U.S. Patent No. 7,951,787

Certification and Request for Prioritized Examination Under 37 CFR 1.102(e), U.S. Patent Application Serial No. 14/229,292 (March 28, 2014)

TrackOne Grant, U.S. Patent Application Serial No. 14/229,292 (May 6, 2014)

Notice of Allowability, U.S. Patent Application Serial No. 14/229,292 (May 23, 2014)

L. W. Brox et al., Studies on the Growth Inhibition and Metabolism of 2'-Deoxy-2'-fluorocytidine in Cultured Human Lymphoblasts, 34 Cancer Research 1838 (1974)

Declaration of David MacMillan, Ph.D.

Curriculum Vitae of David MacMillan, Ph.D.

Complaint, Regents of the Univ. of Minn. v. Gilead Sciences, Inc., No. 0:16-cv-02915-SRN-HB (D. Minn., Aug. 29, 2016)

Iris L. Doerr & Jack J. Fox, Nucleosides. XXXIX. 2'-Deoxy-2'-fluorocytidine, 1-B-D-Arabinofuranoslyl-2-amino-1, 4(2H)-4-iminopyrimidine, and Related Derivatives, 32 Analogs of Cytidine and Isocytidine 1462 (1967)

Gemzar [package insert]. Eli Lilly and Company, Indianapolis, IN; 1996, 2017

WIPO International Publication No. 2005/012327 A2

Petition for Inter Partes Review of U.S. Patent No. 8,815,830

Petitioner's Power of Attorney